These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8267694)

  • 1. Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis.
    Boland GJ; Ververs C; Hené RJ; Jambroes G; Donckerwolcke RA; de Gast GC
    Transpl Int; 1993 Jan; 6(1):34-8. PubMed ID: 8267694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients.
    Nicol DL; MacDonald AS; Belitsky P; Lee S; Cohen AD; Bitter-Suermann H; Lowen J; Whalen A
    Transplantation; 1993 Apr; 55(4):841-6. PubMed ID: 8386404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
    Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
    Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
    Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R
    Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the incidence of cytomegalovirus disease following heart transplantation decreased by prophylactic ganciclovir and CMV-hyperimmunglobulin?
    Cantarovich M; René P; Latter D
    Transpl Int; 1994; 7 Suppl 1():S385-8. PubMed ID: 11271260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients.
    Kocher AA; Bonaros N; Dunkler D; Ehrlich M; Schlechta B; Zweytick B; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2003 Mar; 22(3):250-7. PubMed ID: 12633691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.
    Valantine HA; Luikart H; Doyle R; Theodore J; Hunt S; Oyer P; Robbins R; Berry G; Reitz B
    Transplantation; 2001 Nov; 72(10):1647-52. PubMed ID: 11726825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.
    Aguado JM; Gomez-Sanchez MA; Lumbreras C; Delgado J; Lizasoain M; Otero JR; Rufilanchas JJ; Noriega AR
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1643-5. PubMed ID: 7492123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
    Hibberd PL; Tolkoff-Rubin NE; Cosimi AB; Schooley RT; Isaacson D; Doran M; Delvecchio A; Delmonico FL; Auchincloss H; Rubin RH
    Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of active cytomegalovirus (CMV) infection after heart and kidney transplantation by testing for immediate early antigenemia and influence of cellular immunity on the occurrence of CMV infection.
    Boland GJ; de Gast GC; Hené RJ; Jambroes G; Donckerwolcke R; The TH; Mudde GC
    J Clin Microbiol; 1990 Sep; 28(9):2069-75. PubMed ID: 2172297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
    Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
    Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.